The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
Open accessAbstract
BACKGROUND: Platinum-based concurrent chemoradiotherapy is the standard of care for patients with locoregionally advanced nasopharyngeal carcinoma. Additional gemcitabine and cisplatin induction chemotherapy has shown promising efficacy in phase 2 trials. METHODS: In a parallel-group, multicenter, randomized, controlled, phase 3 trial, we compared gemcitabine and cisplatin as induction chemotherapy plus concurrent chemoradiotherapy with concurrent chemoradiotherapy alone. Patients with locoregionally advanced nasopharyngeal carcinoma were randomly assigned in a 1:1 ratio to receive gemcitabine (at a dose of 1 g per square meter of body-surface area on days 1 and 8) plus cisplatin (80 mg per square meter on day 1), administered every 3 weeks for three cycles, plus chemoradiotherapy (concurrent cisplatin at a dose of 100 mg per square meter every 3 weeks for three cycles plus intensity-modulated radiotherapy) or chemoradiotherapy alone. The primary end point was recurrence-free survival (i.e., freedom from disease recurrence [distant metastasis or locoregional recurrence] or death from any cause) in the intention-to-treat population. Secondary end points included overall survival, treatment adherence, and safety. RESULTS: A total of 480 patients were included in the trial (242 patients in the induction chemotherapy group and 238 in the standard-therapy group). At a median follow-up of 42.7 months, the 3-year recurrence-free survival was 85.3% in the induction chemotherapy group and 76.5% in the standard-therapy group (stratified hazard ratio for recurrence or death, 0.51; 95% confidence interval [CI], 0.34 to 0.77; P = 0.001). Overall survival at 3 years was 94.6% and 90.3%, respectively (stratified hazard ratio for death, 0.43; 95% CI, 0.24 to 0.77). A total of 96.7% of the patients completed three cycles of induction chemotherapy. The incidence of acute adverse events of grade 3 or 4 was 75.7% in the induction chemotherapy group and 55.7% in the standard-therapy group, with a higher incidence of neutropenia, thrombocytopenia, anemia, nausea, and vomiting in the induction chemotherapy group. The incidence of grade 3 or 4 late toxic effects was 9.2% in the induction chemotherapy group and 11.4% in the standard-therapy group. CONCLUSIONS: Induction chemotherapy added to chemoradiotherapy significantly improved recurrence-free survival and overall survival, as compared with chemoradiotherapy alone, among patients with locoregionally advanced nasopharyngeal carcinoma. (Funded by the Innovation Team Development Plan of the Ministry of Education and others; ClinicalTrials.gov number, NCT01872962.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029
Cox, J. D., Stetz, J., & Pajak, T. F. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)00060-c · Cited by 4,792
Partial residuals for the proportional hazards regression model
SCHOENFELD, D. (1982) · Biometrika · doi:10.1093/biomet/69.1.239 · Cited by 3,111
Fundamentals of Clinical Trials
Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015) · doi:10.1007/978-3-319-18539-2 · Cited by 2,237
Al-Sarraf, M., LeBlanc, M., Giri, P. G., Fu, K. K., Cooper, J., Vuong, T., Forastiere, A. A., Adams, G., Sakr, W. A., Schuller, D. E., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1310 · Cited by 2,222
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
Vermorken, J. B., Remenar, E., van Herpen, C., Gorlia, T., Mesia, R., Degardin, M., Stewart, J. S., Jelic, S., Betka, J., Preiss, J. H., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071028 · Cited by 1,719
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
Posner, M. R., Hershock, D. M., Blajman, C. R., Mickiewicz, E., Winquist, E., Gorbounova, V., Tjulandin, S., Shin, D. M., Cullen, K., Ervin, T. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070956 · Cited by 1,705
Sun, Y., Li, W.-F., Chen, N.-Y., Zhang, N., Hu, G.-Q., Xie, F.-Y., Sun, Y., Chen, X.-Z., Li, J.-G., Zhu, X.-D., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30410-7 · Cited by 950
Self-citationSample Size Calculations in Clinical Research
Chow, S.-C., Wang, H., & Shao, J. (2003) · CRC Press eBooks · doi:10.1201/9780203911341 · Cited by 807
Cited by
Mody, M. D., Rocco, J. W., Yom, S. S., Haddad, R. I., & Saba, N. F. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01550-6 · Cited by 847
Bossi, P., Chan, A. T., Licitra, L., Trama, A., Orlandi, E., Hui, E. P., Halámková, J., Mattheis, S., Baujat, B., Hardillo, J., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.12.007 · Cited by 447
Zschaeck, S., Li, Y., Lin, Q., Beck, M., Amthauer, H., Bauersachs, L., Hajiyianni, M., Rogasch, J., Ehrhardt, V. H., Kalinauskaite, G., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0236841 · Cited by 28
Self-citation
Metadata
- Authors
- Zhang, Y., Chen, L., Hu, G.-Q., Zhang, N., Zhu, X.-D., Yang, K.-Y., Jin, F., Shi, M., Chen, Y.-P., Hu, W.-H., Cheng, Z.-B., Wang, S.-Y., Tian, Y., Wang, X.-C., Sun, Y., Li, J.-G., Li, W.-F., Li, Y.-H., Tang, L.-L., Mao, Y.-P., Zhou, G.-Q., Sun, R., Liu, X., Guo, R., Long, G.-X., Liang, S.-Q., Li, L., Huang, J., Long, J.-H., Zang, J., Liu, Q.-D., Zou, L., Su, Q.-F., Zheng, B.-M., Xiao, Y., Guo, Y., Han, F., Mo, H.-Y., Lv, J.-W., Du, X.-J., Xu, C., Liu, N., Li, Y.-Q., Chua, M. L. K., Xie, F.-Y., Sun, Y., & Ma, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-09-19
- Volume
- 381
- Issue
- 12
- Pages
- 1124-1135
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2947165726
- Cited by
- 927
- References
- 23
- FWCI
- 84.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. https://app.cochat.ai/papers/10.1056/nejmoa1905287
- The paper
- Zhang, Y., Chen, L., Hu, G.-Q., Zhang, N., Zhu, X.-D., Yang, K.-Y., Jin, F., Shi, M., Chen, Y.-P., Hu, W.-H., Cheng, Z.-B., Wang, S.-Y., Tian, Y., Wang, X.-C., Sun, Y., Li, J.-G., Li, W.-F., Li, Y.-H., Tang, L.-L., . . . Ma, J. (2019). Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1905287
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.